Clinical Trial Update: A Long-Term Extension Study of AT2101 (Afegostat Tartrate) in Type 1 Gaucher Patients [Phase 2]

View source ↗

Summary

Long-term extension study update of AT2101 (Afegostat Tartrate) in patients with Type 1 Gaucher disease completed, with results posted in 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gaucher Disease
• Gaucher Disease Type

Drugs mentioned

• AT2101

Snippet

Sponsor: Amicus Therapeutics | Conditions: Gaucher Disease, Type 1 Gaucher Disease | Phase 2 | Status: COMPLETED | Results posted: 2018-08-15